Remicade

Remicade

  • August 2018 •
  • 86 pages •
  • Report ID: 5779815 •
  • Format: PDF
Drug Overview
Remicade (infliximab; Johnson and Johnson/Merck and Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis. Remicade has also been granted orphan drug status for Kawasaki disease in Japan.